Crescent Biopharma Inc.
CBIO | NASDAQ
$12.88
-$0.60 (-4.45%)
Nov 2, 2026, 12:02 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 10.84M | n/a | 10K | 75K | 1.16M | 10.16M |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 10.84M | n/a | 10K | 75K | 1.16M | 10.16M |
Operating Income | -152.63M | -49.9M | -39.28M | -47.4M | -63.45M | -51.51M |
Interest Income | 2.88M | 1M | 2.38M | 714.52K | 19.77K | 482.49K |
Pretax Income | -151.94M | -48.52M | -36.9M | -46.69M | -63.43M | -51.03M |
Net Income | -153.94M | -48.52M | -36.9M | -46.69M | -63.43M | -51.03M |
Selling & General & Admin | 25.39M | 16.32M | 19.21M | 19.09M | 17.12M | 16.74M |
Research & Development | 138.09M | 28.06M | 20.07M | 28.39M | 47.49M | 44.93M |
Other Expenses | n/a | 5.51M | 637 | 443 | n/a | n/a |
Operating Expenses | 163.48M | 49.9M | 39.29M | 47.48M | 64.61M | 61.67M |
Interest Expense | 2.19M | 852K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 163.48M | 49.9M | 39.29M | 47.48M | 64.61M | 61.67M |
Income Tax Expense | 2M | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 10.41M | 767.58K | 633.42K | 525.31K | 514.53K | 457.21K |
Shares Outstanding (Diluted) | 10.41M | 767.58K | 633.42K | 525.31K | 514.53K | 457.21K |
EPS (Basic) | -14.78 | -63.22 | -58.25 | -88.88 | -123.27 | -111.60 |
EPS (Diluted) | -14.78 | -63.22 | -58.25 | -88.88 | -123.27 | -111.60 |
EBITDA | -149.67M | -44.17M | -39.12M | -47.2M | -63.18M | -51.24M |
EBIT | -149.76M | -44.21M | -39.27M | -47.4M | -63.45M | -51.51M |
Depreciation & Amortization | 84K | 35.17K | 153.3K | 207.15K | 264.6K | 270.75K |
Add to Watchlist
Select watchlists to add or remove CBIO